Prostate Adenocarcinoma TransCutaneous Hormones (PATCH)
A Randomized-Controlled Trial of Transcutaneous Oestrogen Patches Versus LHRH Agonists in Prostate Cancer
Sponsor: Medical Research Council
A PHASE3 clinical study on Anemia and Cardiovascular Complications, this trial is ongoing. The trial is conducted by Medical Research Council and has accumulated 8 data snapshots since 2006. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Dec 2022 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jan 2021 — Dec 2022 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jun 2018 — Dec 2020 [monthly]
Recruiting PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Mar 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medical Research Council
- University College, London
For direct contact, visit the study record on ClinicalTrials.gov .